Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction

INTRODUCTION: Neither the pathophysiology nor an effective treatment for heart failure with preserved ejection fraction (HFpEF) has been elucidated to date. The purpose of this ongoing study is to elucidate the pathophysiology and prognostic factors for patients with HFpEF admitted to participating...

Descripción completa

Detalles Bibliográficos
Autores principales: Suna, Shinichiro, Hikoso, Shungo, Yamada, Takahisa, Uematsu, Masaaki, Yasumura, Yoshio, Nakagawa, Akito, Takeda, Toshihiro, Kojima, Takayuki, Kida, Hirota, Oeun, Bolrathanak, Sunaga, Akihiro, Kitamura, Tetsuhisa, Dohi, Tomoharu, Okada, Katsuki, Mizuno, Hiroya, Nakatani, Daisaku, Iso, Hiroyasu, Matsumura, Yasushi, Sakata, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566724/
https://www.ncbi.nlm.nih.gov/pubmed/33060085
http://dx.doi.org/10.1136/bmjopen-2020-038294
Descripción
Sumario:INTRODUCTION: Neither the pathophysiology nor an effective treatment for heart failure with preserved ejection fraction (HFpEF) has been elucidated to date. The purpose of this ongoing study is to elucidate the pathophysiology and prognostic factors for patients with HFpEF admitted to participating institutes. We also aim to obtain insights into the development of new diagnostic and treatment methods by analysing patient background factors, clinical data and follow-up information. METHODS AND ANALYSIS: This study is a prospective, multicentre, observational study of patients aged ≥20 years admitted due to acute decompensated heart failure with preserved left ventricular ejection fraction (≥50%) and elevated N-terminal-pro brain natriuretic peptide (NT-proBNP) (≥400 pg/mL). The study began in June 2016, with the participation of Osaka University Hospital and 31 affiliated facilities. We will collect data on history in detail, accompanying diseases, quality of life, frailty score, medication history, and laboratory and echocardiographic data. We will follow-up each patient for 5 years, and collect outcome data on mortality, cause of death, and the number and cause of hospitalisation. The target number of registered cases is 1500 cases in 5 years. ETHICS AND DISSEMINATION: The protocol was approved by the Institutional Review Board (IRB) of Osaka University Hospital on 24 February 2016 (ID: 15471), and by the IRBs of the all participating facilities. The findings will be disseminated through peer-reviewed publications and conference presentations.